ArticleGut pathogens2026
Fecal microbiota from hepatitis B-infected individuals alters triglyceride metabolism and microbial pathways in mice.
Article in Gut pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis study investigates the impact of chronic hepatitis B virus infection on triglyceride metabolism through alterations in the gut microbiome, using a faecal microbiota transplantation (FMT) mouse model.
methodsThis shotgun metagenomic analysis was conducted using stored samples from a previously published FMT experiment. Nineteen mice with sufficient faecal DNA for sequencing were included, comprising ten mice transplanted with microbiota from two hepatitis B virus (HBV)-infected donors and nine mice transplanted with microbiota from two non-infected donors. Shotgun metagenomic sequencing was performed on stool collected two weeks post-FMT, and metabolic parameters were compared between two and five weeks post-transplantation.
resultsMice receiving microbiota from HBV-infected individuals exhibited lower triglyceride levels (100.05 ± 10.82 vs. 111.69 ± 12.27 mg/dL, p = 0.04) at five weeks post-FMT compared with those receiving microbiota from non-infected individuals. HBV-positive mice also showed higher microbial diversity and an increased abundance of short-chain fatty acid–producing bacterial species, including Anaerofustis stercorihominis, Bacteroides cellulosilyticus, and Butyricimonas virosa. Shotgun analysis revealed reduced activity in the pentose phosphate pathway and galactitol degradation pathways, both involved in carbohydrate and fatty acid metabolism, alongside unique bile acid dihydroxylation pathways.
conclusionsThese findings indicate that gut microbiota with chronic HBV infection modulate host lipid metabolism, particularly triglyceride levels, through distinct microbial species and metabolic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.